Kraj: Kanada
Język: angielski
Źródło: Health Canada
CONJUGATED ESTROGENS
PFIZER CANADA ULC
G03CA57
CONJUGATED ESTROGENS
0.625MG
TABLET
CONJUGATED ESTROGENS 0.625MG
ORAL
30/100/1000
Prescription
ESTROGENS
Active ingredient group (AIG) number: 0106442006; AHFS:
CANCELLED POST MARKET
2017-08-02
_Premarin_ _ (conjugated_ _ _ _estrogens tablets, CSD) _ _Page 1 of 42_ COMPLETE PRESCRIBING INFORMATION Pr PREMARIN ® (conjugated estrogens tablets, CSD) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Pfizer Canada Inc., Licensee 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Date of Revision: January 10, 2012 Submission Control No: 148504 _Premarin_ _ (conjugated_ _ _ _estrogens tablets, CSD) _ _Page 2 of 42_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................19 DOSAGE AND ADMINISTRATION ................................................................................22 OVERDOSAGE...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY...............................................................25 STORAGE AND STABILITY ............................................................................................28 SPECIAL HANDLING INSTRUCTIONS..........................................................................28 DOSAGE FORMS, COMPOSITION AND PACKAGING................................................28 PART II: SCIENTIFIC INFORMATION ...............................................................................30 PHARMACEUTICAL INFORMATION .... Przeczytaj cały dokument